biomed devic servic
diagnost tool
price close busi januari
diagnost tool
 review
wild ride featur high-high anxiety-produc low believ
wall street overreact fed chairman powel polici normal
think miss help prove trade war benefit nobodi think
china trade deal get done think us growth low unemploy still
histor low interest rate bad backdrop us equiti
disappoint us market gener neg return name
 russel respect recent
volatil time alarm histor abnorm
top pick lh gener full
year return comparison return
top pick lh gener full
year return comparison return
coverag univers gener return inclus acquisit
abax premium exclud abaxi deal coverag return
diagnost outperform broader indic expect new test
gener clinic econom util patient payor pace posit return
expect ipo uptick acquisit help share
buyback investor hunt disrupt growth compani intersect
healthcar technolog focu diagnost precis medicin
top pick
 domin leader high visibl double-digit top bottom line
growth think penetr developed-world
 also domin industri leader start team pfizer
bring innov cologuard test help curb colon cancer death
us year penetr look advanc develop new
 largest medic point-of-car diagnost pure-play execut well
multipl iron fire busi pipelin unexpect initi legal
rule prompt major pullback share expect revers
 anim health remain hot load catalyst believ
would formid takeout candid compani like mar
 leader pre-net test launch signatera liquid biopsi test
cancer patient lung breast colon expect acog endors average-
risk nipt aet follow market cap
 model double-digit top line dna genotek hiv self-test microbiom
bottom line growth trade rev trade
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
diagnost tool
 review
wild ride featur high-high anxiety-produc low believ
wall street overreact fed chairman powel monetari polici normal
unclear optimist tariff war fear china like eas
fed like hold pat rate hike fear hope
investor look us growth low unemploy still histor low
interest rate determin bad backdrop us equiti
diagnost outperform market expect test gener clinic
econom util patient payor pace posit return expect
ipo uptick investor hunt growth disrupt
healthcar technolog spend time dig diagnost
precis medicin major winner ghdx
disappoint us market gener neg return name
 russel respect recent
volatil time alarm histor abnorm
top pick lh gener full
year return comparison gener total return
top pick lh gener full
year return comparison gener total return
coverag univers gener total return inclus
acquisit abax premium exclud abaxi deal coverag
return market cap coverag univers return
exclud hold-rat vrml return figur
top pick
 domin leader high visibl double-digit top bottom line
growth think get start mani respect global popul
sequenc studi liquid biopsi singl cell sequenc pace growth
china revenu though think tariff concern like abat
 domin leader start team pfizer bring innov
cologuard test help curb colon cancer death us year
remain penetr cologuard-tam alon north billion
 largest medic point-of-car diagnost pure-play execut
well multipl iron busi pipelin unexpect initi legal rule
prompt major pullback share expect revers
 anim health remain hot load catalyst believ
would formid takeout candid compani like mar
 leader liquid biopsi pre-nat test launch promis
signatera liquid biopsi test cancer patient cancer like lung breast
colon bladder expect acog endors average-risk nipt
aet follow coverag hope launch initi test organ
transplant reject follow market leader rate kidney
market market cap hover
expect rebound disappoint model
double-digit top bottom line growth rev
figur return canaccord genuiti coverag vs major indic canaccord diagnost tool coverag mark massaro
top pick top pick lh
diagnost tool
compani report canaccord genuiti estim ev/rev multipl valuat end revenu earn growth cg estim end lh remov top pick
list octob remov top pick list may initi ad research coverag octob abaxi agre acquir zoeti may
drop coverag abaxi septemb
buy reiter pt
excel gener return one year return
sinc reach peak late
septemb stock market correct pain particularli growth stock
volatil market condit often allow investor enter buy stock
attract entri point
call must stock reaffirm view
reap reward superb novaseq instrument launch
enabl life scienc research explor number applic new
updat sinc analyst day ad nipt
carrier screen rare undiagnos diseas babi
consum genom oncolog pop seq
estim revis least develop world alon
hub number precis medicin greenshoot spoke
get start set multi-year cycl rapid growth physician-
order prenat carrier screen test consumer-ord genet test
power genotyp whole-exom sequenc popul
diagnost tool
sequenc studi run govern across globe tissue-bas cancer
test blood base cancer studi test liquid biopsi
peopl ever sequenc develop world popul
estim genotyp world develop
popul estim cancer patient babi rare
diseas sequenc respect cost whole genom
sequenc wg drop person lower today
expect within year see path peopl sequenc
next year driven pop seq liquid biopsi studi
cancer children think sequenc
project given lead accuraci throughput cost note we could add
million count consum genotyp to-dat
envis year
earli novemb announc acquisit long-read sequenc
leader pacbio ev next year
consensu revenu pacbio premium sharehold
pacbio deal mark largest announc acquisit year
bought solexa deal ad sharehold valu
view one best acquisit all-tim pacbio deal
remain subject regulatori clearanc believ may pose challeng
given estim togeth produc
world genom inform
trade adj ep revenu
estim billion dont see near-term competit risk
expect continu advanc product leadership market year
buy reiter pt
alway go strategi except exact
landmark co-promot agreement togeth
two aim curb colon cancer death us year provid
access innov cologuard colorect screen test
deal without execut risk posit
agreement manag commit long-term success
unclear exact number rep co-promot cologuard
estim combin sale forc given expand sale reach
increas frequenc call doc think adequ engin
drive patient rescreen elig patient last cologuard test
see upsid our/street estim model exclud
increment benefit order american age
recommend screen ac high-risk american colon cancer
anoth peopl all-in would total american time
colon cancer test beyond cologuard think liver test
launch eventu model also exclud acquisit biomatrica
american elig screen never
screen thu earli day penetr goal
penetr time
focu center follow catalyst commerci execut
rep estim rep new
coverag decis contract increas push cologuard reorder
diagnost tool
develop liver cancer surveil test anticip launch earli
eoy ldt though regulatori path decis remain tbd
liquid biopsi test lung nodul pancreat pursu new acquisit
partnership
consid larg health system one biggest opportun cologuard
growth next year primari care physician
employ affili larg health system cologuard present
face challeng barrier adopt larg health system given
diplomat often complex process establish standard care cancer
monitor treatment howev believ strong tie
larg health system help break ice ramp penetr
note high multipl stock time stock
level requir excel execut think stock
peak reach provid breath room multipl
opinion near term risk includ possibl near-term disrupt
sale forc focu given start collabor ie know
much overlap exist exist rep territori rep
know number rep deploy sell cologuard cologuard
priorit rep product product hope product
cologuard diagnost learn curv therapeut rep
assum sale forc rep minimum details/year
requir agreement rep would respons
details/year details/day assum work day calendar year
math conduct linkedin search pfizer intern medicin sale
filter profession current employ return
result medium long-term risk includ success
collabor pharma compani awar one
diagnost compani may termin agreement detail
fewer clinician calendar year
trade revenue estim model
revenu growth elit level growth coverag also
gener elit gross margin see path gm time
buy reiter pt
largest remain stand-alone human medic point-of-car dx compani
believ time could draw interest larger compani like bid
aler got abbott despit adequ sharehold return
follow spectacular return qdel stock trade
high larg due unexpect advers rule legal
battl subsidiari beckman coulter
typic unexpect chang think relat legal matter surpris
market investor shoot first ask question later believ qdel sharp
decemb sell-off prime exampl inaccur price worst case
believ win result impact motion
trial august reach favor settlement stock price
worst case relat legal matter beckman opinion
diagnost tool
consid misunderstood legal case san diego superior court
announc decemb intend void provis beckman
coulter suppli agreement restrict beckman manufactur sell
directli competit cardiac health assay action halt stock
sent thin trade like bear near-term legal
overhang view declin overblown part sinc preced edward
case judg referenc beckman-qdel case appear inappropri
appeal case time would take beckman realist
compet year view
oper execut impress sinc announc acquisit
divest asset year ago assay program
activ develop continu assess full plate opportun
expect accret upon close/launch august obtain fda
approv first fda-clear rapid minut clia-waiv lyme diseas
test meet signific unmet need given rise preval lyme
diseas lack anoth point-of-car lyme test indic interest
build surpris see upsid modest lyme
revenu model front indic call
activ vet deal anoth hand deck recal
indic analyst day plan acquir revenu
trade revenu estim adj
ep estim trade consensu ebitda
estim well point-of-car peer group averag qdel cheap
valuat come despit compani never-before-seen scarciti valu qualiti
point-of-car stand-alone compani mention never-before-avail on-going
revenu cost synergi opportun post acquisit triag bnp
abbott multipl inorgan opportun multipl organ growth
opportun like number new assay launch next year
buy reiter pt
essenti bridg year yet still return
sharehold despit up-and-down commerci execut importantli us
anim health market remain hot set motion major catalyst
set think time stock right
anim health trend remain strong market consolid turn
global last remain small pure play anim health diagnost compani
obviou fit least mar henri schein anim health vet
first choic newco someon els view track roll flurri
big new product think much room grow go
global
analyst day may announc plan roll number new
analyz element fecal imag analyz peg
respect
august announc plan launch element togeth
element plan launch may launch element
element togeth target ou launch earli coincid ou
push larg partner add roll-out new product
began ad addit sale rep june near complet
sale forc expans field rep new rep onboard
diagnost tool
parallel new product launch look correl breadth offer
servic number rep field
opinion develop meaning understand ou
push complet spin-off form schein
expect complet earli plan establish beach-head
germani add hand rep key eu countri look complement
mani rep much larger partner meanwhil begun
expans australia new zealand
recal may analyst day initi revenu target
impli compound-annual-growth-rate revenu base
indic new product launch expect contribut
growth balanc driven legaci product growth intern
expans impli hska compound-annual-growth-rate growth consum
y/i growth digit imag also initi gross margin
oper margin target respect impli
gm om expans per year
trade revenu estim
point-of-car peer group trade estimate
buy trim pt
leader liquid biopsi pre-nat test multipl wave growth
ahead one favorit small cap growth stock coverag despit
favor return sharehold trade
peak follow rapid appreci earli stock
pull back part due manag sell small miss guid due
newer product take longer recogn revenu sharp correct
market natera trade revenue estim
y/i ahead catalyst-rich includ revis acog bulletin support
average-risk non-invas prenat test think near-term inevit
see and/or aet cover average-risk nipt post acog
bulletin sign addit partnership ex-pharma similar qiagen
agreement partnership pharma similar agreement lead
drug compani bristol-mey squibb launch signatera liquid biopsi
cancer patient updat kidney launch launch
panorama generead cog reduct get paid
microdelet test market cap estim
believ smid investor radar
juli american colleg obstetrician gynecologist acog withdrew
practic bulletin doubt util non-invas prenat test nipt
average-risk women left acog practic bulletin
support weve sinc spoken coupl nipt compani
express optim retir may lead newer bulletin
support averag risk nipt earli next month think larg commerci
payor like aet and/or could follow acog endors issu posit
coverag decis average-risk nipt major catalyst present
model posit endors acog aet average-risk birth
thu posit develop would addit estim
announc septemb agreement lead drug compani
bristol-mey squibb rate use signatera liquid biopsi assay
biomark opdivo phase studi non-smal cell lung cancer regard
agreement valid biopharma compani interest use
diagnost tool
signatera biomark identif capabl investig novel treatment
approach signatera first circul tumor dna liquid biopsi assay
use prospect outcom studi inform adjuv nsclc treatment
think deal bm could expand studi advanc phase
could turn deal think meanwhil talk
drug compani similar indic ie perhap deal keytruda well
cancer state includ colon bladder cancer
plan enter blood base kidney transplant reject test market
sometim suspect like time think like
expand offer test organ like heart lung liver
peg
demonstr sensit ahead first-to-market lab
sensit though ampl amount investor debat
whether two test compar one anoth think market
obvious larg enough least two good player note
model organ transplant revenu model
acknowledg conserv assumpt particularli beyond
lower pt revenu estim
discount back year discount rate
buy reiter pt
despit deliv averag top-lin growth first three quarter
orasur stock declin enterpris valu
start share investor
frustrat regard osur lack guidanc near-term perform
molecular collect busi believ declin stock overblown
trade low end histor valuat rang believ execut
level-set guid mark mark upsid osur stock near term
larg custom discount kit recent holiday
season similar last year result explos growth expect good overal
holiday season dtc test think mark upsid result
within infecti diseas segment believ possibl
resurrect one hepat hcv countrywid erad project
street model zero wise view still activ dialogu
sever countri hcv erad fact manag indic
larg countri renew suppli agreement still
switch hcv test provid fund come think
could possibl win back custom would obvious mark materi upsid
our/street estim view free call option
orasur ceo steve tang indic us novemb confer
bottom first inning molecular collect busi suggest
confid double-digit growth segment next sever year
first time heard long-term growth rate beyond one quarter
affirm think double-digit growth year orasur believ
three misunderstood aspect stock busi develop
hunt microbiom hcv erad manag believ
microbiom larger saliva genom busi futur sinc
oftentim peopl take multipl sampl monitor complex chang gut
skin microbiom buy-back author put work
mention cash balanc sheet
orasur trade revenu y/i
consensu ebitda vs point-of-car peer group
diagnost tool
detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact inform appear front page report
diagnost tool
diagnost tool
diagnost tool
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
diagnost tool
diagnost tool
ourc compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
diagnost tool
diagnost tool
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
diagnost tool
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
diagnost tool
diagnost tool
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
diagnost tool
diagnost tool
diagnost tool
